Is Egrifta (Tesamorelin) Legal in Pennsylvania?

The Short Answer: Yes, Tesamorelin Is Legal in Pennsylvania

Tesamorelin has full FDA-approved drug status. Pennsylvania enforces federal pharmaceutical law and adds no independent prohibition on the molecule. A Pennsylvania-licensed prescriber may legally write a prescription for Egrifta today, and a licensed pharmacy may legally dispense it.

The clinical context of the prescription does matter. The FDA label restricts Egrifta to adults with HIV-associated lipodystrophy, and off-label use of the brand product or compounded tesamorelin carries different coverage, liability, and clinical-monitoring expectations. Each scenario is explained in the sections below.

Federal Legal Framework: How Egrifta Gets Its Status

FDA Approval History

The FDA approved Egrifta (tesamorelin 2 mg/vial) on November 10, 2010, under NDA 022505, manufactured by Theratechnologies. [1] That approval was specifically for "the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy." A second formulation, Egrifta SV (a single-vial, room-temperature-stable version), received approval in 2019 under NDA 210595. [2]

Because tesamorelin is an FDA-approved drug, it sits firmly inside the federal pharmaceutical system, not in the research-chemical gray zone occupied by unapproved peptides. It is not listed on the DEA's controlled substances schedules. It is not on the FDA's list of bulk drug substances that may not be compounded (the so-called "Category 2" list under 503A). [3]

Controlled Substance Classification

Tesamorelin does not appear on any schedule of the Controlled Substances Act. [4] It is a growth-hormone releasing hormone (GHRH) analogue, not a growth hormone itself, and the DEA has not placed synthetic GHRH analogues on any scheduling list. This means a DEA registration is not required specifically to prescribe tesamorelin, though Pennsylvania prescribers still need a valid state medical license and, for any controlled medications prescribed alongside it, a current DEA number.

FDA's Bulk Compounding Lists

The 2013 Drug Quality and Security Act (DQSA) created two pathways that govern compounding pharmacies:

• 503A pharmacies are patient-specific compounding pharmacies. They may compound a drug that is "essentially a copy" of an approved drug only when there is a clinical difference documented by the prescriber, or when the commercially available product is on an FDA drug shortage list. Tesamorelin is not currently on the 503A "Category 2" prohibited list, meaning a 503A pharmacy may compound it for individual patients when a valid prescription documents medical necessity. [3]
• 503B outsourcing facilities may produce tesamorelin in larger quantities without patient-specific prescriptions, provided it is not on the FDA's "difficult-to-compound" list and meets Current Good Manufacturing Practice (CGMP) standards. [5]

Clinicians ordering compounded tesamorelin should confirm the pharmacy holds the appropriate federal registration. The FDA's registered outsourcing facility database is searchable at fda.gov. [5]

Pennsylvania State Law: What the Commonwealth Adds (and Doesn't)

Pennsylvania Pharmacy Act

The Pennsylvania Pharmacy Act (63 P.S. § 390-1 et seq.) governs dispensing within the state. It requires that any drug dispensed to a Pennsylvania patient be dispensed by a pharmacy holding a current Pennsylvania Board of Pharmacy license, pursuant to a valid prescription from a licensed prescriber. The Act does not create a separate state-level classification system for peptide hormones. Tesamorelin is therefore legal to dispense in Pennsylvania under the same rules that apply to any other legend (prescription-required) drug. [6]

Pennsylvania Medical Practice Act

The Medical Practice Act of 1985 (63 P.S. § 422.1 et seq.) permits Pennsylvania-licensed physicians and osteopathic physicians to prescribe any FDA-approved drug within the scope of their medical judgment, including off-label uses, provided the prescribing meets a standard of care. [7] The same broad prescribing authority extends to certified registered nurse practitioners (CRNPs) and physician assistants (PAs) under their respective practice acts, subject to any collaborative-agreement requirements that still apply.

Off-Label Use in Pennsylvania

Off-label prescribing is not illegal in Pennsylvania or in any U.S. State. The AMA's Council on Ethical and Judicial Affairs has explicitly stated that "physicians may prescribe drugs for uses not approved by the FDA when there is sound scientific evidence or established clinical practice to support such use." Off-label tesamorelin use (for example, in non-HIV patients with visceral adiposity or growth hormone deficiency) is therefore legally permissible in Pennsylvania, though payers may deny reimbursement and the prescriber assumes clinical responsibility for demonstrating a rationale. [7]

No Pennsylvania-Specific Peptide Ban

Several states have enacted rules restricting specific peptides. Pennsylvania has not enacted any such provision for tesamorelin or for GHRH analogues as a class. A review of the Pennsylvania Code (Title 49, Professional and Vocational Standards) and Title 28 (Health and Safety) as of this article's review date shows no additional state restriction on prescribing, dispensing, or possessing tesamorelin. Patients and clinicians should verify current regulations with the Pennsylvania Department of State's Bureau of Professional and Occupational Affairs if they have specific compliance questions.

Clinical Background: What Tesamorelin Actually Does

Mechanism of Action

Tesamorelin is a 44-amino-acid synthetic analogue of endogenous growth hormone releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates pulsatile growth hormone secretion, which in turn raises insulin-like growth factor 1 (IGF-1). Unlike exogenous recombinant human growth hormone (rhGH), tesamorelin preserves the normal pulsatile pattern of GH release and avoids the supraphysiologic IGF-1 spikes associated with direct GH injection. [8]

Clinical Evidence

The two key Phase 3 trials (LIPO-010 and LIPO-011, combined N=816 HIV-positive adults) showed that tesamorelin 2 mg/day reduced visceral adipose tissue (VAT) by a mean of 15.2% at 26 weeks compared with 1.1% in the placebo arm (P<0.001). [9] Trunk fat assessed by DEXA also decreased significantly. Fasting glucose and HbA1c changes were not significantly different from placebo over 26 weeks in the primary analysis, though a subset with pre-existing glucose intolerance showed modest elevations that resolved after discontinuation. [9]

A 52-week extension trial (N=273) confirmed that VAT reduction was maintained with continued therapy and reversed within 12 weeks of stopping. [10] This reversibility profile has implications for off-label use: clinicians considering tesamorelin for non-HIV indications should counsel patients that benefits are not permanent without ongoing treatment.

FDA-Approved Indication vs. Off-Label Use

| Use Case | Approved | Evidence Level | |---|---|---| | HIV-associated lipodystrophy (VAT reduction) | Yes (NDA 022505) | Phase 3 RCT [9] | | Non-alcoholic fatty liver disease (NAFLD) | No | Phase 2 pilot data [11] | | Age-related visceral adiposity without HIV | No | Small open-label studies | | GH deficiency augmentation | No | Mechanistic rationale only |

Off-label prescribing for NAFLD has attracted research interest. A 2021 pilot RCT (N=50, Massachusetts General Hospital) found that tesamorelin reduced hepatic fat fraction by 37% versus 10% in controls at 12 months (P=0.02), with no significant liver enzyme elevations. [11] This is an active area of investigation, not a settled indication.

How to Get Egrifta (Tesamorelin) in Pennsylvania

Step 1. Find a Qualified Prescriber

Any Pennsylvania-licensed MD, DO, CRNP, or PA may prescribe tesamorelin. For the FDA-approved indication, an HIV specialist or infectious disease physician typically manages lipodystrophy. For off-label evaluation, an endocrinologist, internist, or telehealth clinician specializing in metabolic medicine may be appropriate. The prescriber must document a clinical rationale in the medical record.

Step 2. Obtain a Diagnosis and Objective Measurements

For the approved HIV-lipodystrophy indication, objective VAT measurement (typically by DEXA or abdominal CT) supports the prescription and is required by most payers. The FDA label specifies that tesamorelin is indicated for adults with HIV who have confirmed excess abdominal fat. For off-label use, the prescriber's documentation of the clinical rationale replaces the label requirement.

Step 3. Choose a Pharmacy

Pennsylvania residents have three dispensing options:

1. Specialty retail pharmacy. Egrifta SV is distributed through specialty pharmacy networks. The manufacturer operates an access program (Theratechnologies TaiMed Access Program) that can assist with prior authorizations and patient-assistance applications for eligible HIV patients.
2. 503A compounding pharmacy. A state-licensed compounding pharmacy holding a Pennsylvania Board of Pharmacy permit may compound tesamorelin for a specific patient when a valid prescription and documented clinical rationale exist. Confirm the pharmacy is not using bulk tesamorelin from an unapproved source.
3. 503B outsourcing facility. A federally registered outsourcing facility may supply tesamorelin to Pennsylvania clinicians or patients without a patient-specific prescription, subject to the facility's own dispensing policies.

Step 4. Insurance and Prior Authorization

Commercial payers and Medicaid generally restrict Egrifta coverage to the FDA-approved HIV-lipodystrophy indication. A prior authorization (PA) request typically requires documentation of HIV diagnosis, antiretroviral therapy duration, and baseline VAT measurement. Medicare Part D covers Egrifta for the labeled indication through some plans. Patients pursuing off-label use should anticipate out-of-pocket costs or explore manufacturer assistance programs.

Telehealth in Pennsylvania

Pennsylvania telehealth law (Act 2020-25) allows prescribing via synchronous audio-video after a valid clinician-patient relationship is established. The Ryan Haight Online Pharmacy Consumer Protection Act requirements apply only to controlled substances; tesamorelin is not controlled, so a telehealth clinician may prescribe it in Pennsylvania following a standard telehealth evaluation without any additional DEA-exception requirement. [12]

Compounded Tesamorelin: Legal Nuances to Understand

The diagram below summarizes the decision pathway a Pennsylvania clinician should apply before ordering compounded versus brand tesamorelin. The key branch points are:

1. Is the patient HIV-positive with confirmed lipodystrophy? If yes, brand Egrifta SV with prior authorization is the preferred legal and reimbursement-optimal path.
2. Is the brand product on FDA shortage or unavailable? If yes, 503A compounding becomes clearly permissible.
3. Is the use off-label (non-HIV)? The prescriber must document the clinical rationale. A 503A pharmacy may compound tesamorelin when the prescriber attests that the compounded preparation has a clinical difference (e.g., altered concentration, different diluent) or that the commercial product is unavailable or inappropriate. Ordering compounded tesamorelin simply to reduce cost when the brand is available and the indication is the same is considered an "essentially a copy" scenario under FDCA 503A and is legally more complex. [3]
4. Is the pharmacy a 503B outsourcing facility? These facilities operate under CGMP and may supply tesamorelin more broadly, but clinicians should verify the facility's registration status on the FDA outsourcing facility registry. [5]

The Pennsylvania State Board of Pharmacy does not currently publish a tesamorelin-specific guidance document. Clinicians with compliance questions may contact the Board directly at (717) 783-7156 or query the Pennsylvania Code through the Pennsylvania Bulletin.

Safety Profile and Monitoring in Pennsylvania Clinical Practice

Common Adverse Effects

The LIPO-010/011 trials reported these adverse effects at rates greater than 5% and higher than placebo: peripheral edema (18.3% vs. 4.5%), arthralgia (13.4% vs. 8.3%), myalgia (5.8% vs. 2.5%), and injection-site reactions (25.5% vs. 14.8%). [9] Most were mild to moderate and resolved without treatment discontinuation.

Glucose Monitoring

Because tesamorelin raises IGF-1 and GH, it may reduce insulin sensitivity in patients with pre-existing metabolic risk. The FDA label recommends monitoring fasting glucose and HbA1c at baseline and periodically during therapy. The American Diabetes Association's 2024 Standards of Medical Care in Diabetes note that growth hormone axis perturbations warrant glucose surveillance in at-risk populations. [13]

Contraindications

Tesamorelin is contraindicated in patients with active malignancy, disruption of the hypothalamic-pituitary axis (e.g., after cranial irradiation or pituitary surgery), and in pregnancy (Category X for fetal harm based on animal data). [1] Patients with a history of malignancy require an oncology consultation before initiation.

IGF-1 Monitoring

Pennsylvania clinicians prescribing tesamorelin off-label for metabolic indications typically follow an IGF-1 level at baseline, at 4 to 6 weeks, and every 3 to 6 months during ongoing therapy. The Endocrine Society's 2011 Clinical Practice Guideline on adult growth hormone deficiency recommends maintaining IGF-1 within age- and sex-adjusted reference ranges during GH-axis therapy. [14] That guideline applies by analogy to tesamorelin monitoring even though the indication differs.

Key Takeaways for Pennsylvania Patients and Prescribers

Tesamorelin is legal in Pennsylvania. Its FDA-approved status, absence from all DEA schedules, and absence from any Pennsylvania-specific restriction list means that a properly written prescription from a licensed clinician is all that stands between a Pennsylvania patient and lawful access.

The practical barriers are clinical and financial, not legal. Insurance prior authorization is the most common obstacle for HIV-lipodystrophy patients. Documenting an evidence-based rationale is the most important step for clinicians pursuing off-label prescribing. Compounding pharmacy selection requires confirming 503A or 503B compliance.

Confirm your prescriber is Pennsylvania-licensed, request baseline VAT imaging or the equivalent diagnostic measure your clinician chooses, and verify your pharmacy's state and federal registration status before your first fill. The FDA's NDA 022505 approval page lists the complete product labeling, which both patients and clinicians should review before initiating therapy. [1]